Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopropionic Acid SCHEMBL8724601 | 1.00 | FFAR3 (0.58) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL26656742 | 0.92 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL5424483 | 0.91 | ACE (0.57) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL436192 | 0.91 | ACE (0.57) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL28066151 | 0.91 | — | — | |
| Mercaptopropionic Acid SCHEMBL10646672 | 0.89 | FFAR3 (0.52) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL5477406 | 0.88 | — | — | |
| Mercaptopropionic Acid SCHEMBL7779538 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL22471706 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Mercaptopropionic Acid SCHEMBL28405529 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305853-B1 | DISPERSION | ASAHI CHEMICAL IND (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-3713982-A1 | RADIATION CURABLE COMPOSITION | Allnex Belgium S.A. (BE) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101865-A1 | RADIATION CURABLE COMPOSITION | ALLNEX BELGIUM S.A. (BE) | 2019-05-31 | — | — | WO | disclosed |
| US-20180171159-A1 | Dispersion | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3305853-A1 | DISPERSION | Asahi Kasei Kabushiki Kaisha (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20160272746-A1 | Photocurable Composition and Molded Article | SOKEN CHEMICAL & ENGINEERING CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-9388308-B2 | Curable resin composition, composition for forming solder resist, dry film and printed wiring board, and laminate and process for preparing the same | TAIYO INK MFG. CO., LTD. (JP) | 2016-07-12 | — | — | US | disclosed |
| EP-2977389-A1 | PHOTO-CURABLE COMPOSITION AND MOLDED ARTICLE | Soken Chemical & Engineering Co., Ltd. (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20150240071-A1 | CURABLE RESIN COMPOSITION, COMPOSITION FOR FORMING SOLDER RESIST, DRY FILM AND PRINTED WIRING BOARD, AND LAMINATE AND PROCESS FOR PREPARING THE SAME | TAIYO INK MFG. CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-8956602-B2 | Delivery of drugs | Landec, Inc. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8524259-B2 | Systems and methods for delivery of materials | LANDEC CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-8399007-B2 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2502619-A2 | Systems and methods for delivery of materials | Landec Corporation (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2500015-A1 | Delivery of drugs | Landec Corporation (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2229150-B1 | SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS | LANDEC CORP (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110009571-A1 | SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS | ALCON RESEARCH, LLC | 2011-01-13 | — | — | US | disclosed |
| US-20100210792-A1 | DRUG DELIVERY | LANDEC CORPORATION | 2010-08-19 | — | — | US | disclosed |
| US-20090263346-A1 | Systems and methods for delivery of drugs | LANDEC CORPORATION | 2009-10-22 | — | — | US | disclosed |
| US-20080269105-A1 | Delivery of drugs | ALCON RESEARCH, LLC | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263346-A1 | Systems and methods for delivery of drugs | CYCS, CTRC, PPIC | FFAR3 2488/4885HDAC3 2082/4885HDAC1 2007/4885 |
| US-20080269105-A1 | Delivery of drugs | ABCB11, ABCB1, LPXN | FFAR3 567/4885HDAC3 404/4885HDAC1 999/4885 |
| US-20100210792-A1 | DRUG DELIVERY | ABCB11, VEGFA, ABCB1 | FFAR3 351/4885HDAC3 773/4885HDAC1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.